NeoStem Provides Further Information Regarding the Design of the Phase 2 PreSERVE AMI Clinical Trial

NEW YORK, Nov 21, 2014 (GLOBE NEWSWIRE via COMTEX) NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced on November 17 initial positive data from its 161 patient Phase 2 PreSERVE AMI (or acute myocardial infarction) clinical trial. NeoStem is sharing additional information to clarify certain facts regarding the Phase 2 PreSERVE trial as we are extremely disappointed, in the face of exciting results, that shareholder value is being diminished by pervasive inaccurate or incomplete statements about the study, said Dr. Robin Smith, Chairman and CEO of NeoStem. By way of background, the goal of a phase 2 trial is to continue to build evidence of the safety and feasibility of the product candidate and to gather evidence of bioactivity and potential efficacy. Ultimately, the hope for a phase 2 study is that it yields information that can guide the design of the next phase study and NeoStem believes this has been achieved. The original ph
http://bit.ly/11m7CBI